Anna Erwin
Family · Corinth, MSNPI 1710249271
Payments from drug & device makers
Across 235 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$900
- Novo Nordisk$331
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$329
- GSK$222
- Pfizer$201
- plus $735 from 19 others
What the payments were for
- Food & beverage$3,752100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,035 |
| AstraZeneca | 39 | $900 |
| Novo Nordisk | 20 | $331 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $329 |
| GSK | 17 | $222 |
| Pfizer | 12 | $201 |
| Sanofi-aventis U.S. LLC | 4 | $133 |
| Lilly USA, LLC | 4 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Novartis | 2 | $54 |
| Biohaven Pharmaceuticals, Inc. | 4 | $53 |
| Halozyme Inc | 2 | $50 |
| Kowa Pharmaceuticals America, Inc. | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Metacel Pharmaceuticals LLC | 1 | $16 |
| Amgen | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Biogen | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,752 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $77,529 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $65,813 |
| MounjaroTirzepatide | 58 | $59,872 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $44,618 |
| FarxigaDapagliflozin Propanediol | 44 | $43,046 |
| Xigduo XrDapaglifloz Propaned/Metformin | 51 | $30,668 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $22,449 |
| VraylarCariprazine Hcl | 16 | $22,162 |
| LinzessLinaclotide | 28 | $20,740 |
| CaplytaLumateperone Tosylate | 11 | $19,036 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $13,055 |
| SynjardyEmpagliflozin/Metformin Hcl | 24 | $11,479 |
| TrulicityDulaglutide | 12 | $11,068 |
| JardianceEmpagliflozin | 16 | $9,086 |
| MyrbetriqMirabegron | 17 | $7,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $900 | $113,659133 claims |
| Novo NordiskOzempic | $331 | $77,52980 claims |
| Lilly USA, LLCMounjaro, Trulicity | $61 | $70,94070 claims |
| GSKTrelegy Ellipta | $222 | $44,61858 claims |
| AbbVieVraylar, Linzess | $1,035 | $42,90244 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $133 | $22,44920 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $329 | $19,03611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.
Other family in Corinth
- Phyllis FiveashCorinth$12K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.